目的 探究活血通脈片聯(lián)合曲美他嗪治療冠心病的臨床效果。方法 選取2015年5月-2016年2月在臨高縣人民醫(yī)院心內(nèi)科進行治療的冠心病患者60例，根據(jù)治療方案的差別分成對照組與治療組，每組各30例。所有患者均給予常規(guī)治療。對照組口服鹽酸曲美他嗪片，20 mg/次，3次/d。治療組在對照組基礎(chǔ)上口服活血通脈片，5片/次，3次/d。兩組患者均連續(xù)治療4周。觀察兩組的臨床療效，比較兩組患者治療前后血清炎性因子、血管內(nèi)皮功能因子和心功能指標改善情況。結(jié)果 治療后，對照組和治療組總有效率分別為80.00%、96.67%，兩組總有效率比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組患者超敏C-反應(yīng)蛋白（hs-CRP）、腫瘤壞死因子-α（TNF-α）和丙二醛（MDA）水平較治療前明顯下降，同組治療前后比較差異具有統(tǒng)計學(xué)意義（P<0.05）；且治療組上述血清炎性因子水平降低更明顯，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組患者內(nèi)皮素-1（ET-1）水平均較治療前明顯下降，NO、降鈣素基因相關(guān)肽（CGRP）水平較治療前明顯升高，同組治療前后比較差異具有統(tǒng)計學(xué)意義（P<0.05）；且治療組這些觀察指標的改善程度優(yōu)于對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組患者左心室舒張末期內(nèi)徑（LVEDD）和左室后壁舒張期直徑（LVPWd）明顯降低，左心室射血分數(shù)（LVEF）指標升高，同組比較差異具有統(tǒng)計學(xué)意義（P<0.05）；且治療組這些心功能指標改善程度優(yōu)于對照組的，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。結(jié)論 活血通脈片聯(lián)合曲美他嗪治療冠心病療效顯著，可明顯改善患者心臟功能和血管內(nèi)皮功能，降低炎性因子水平，具有一定的臨床推廣應(yīng)用價值。

Objective To investigate the clinical curative effect of Huoxue Tongmai Tablets combined with trimetazidine in treatment of coronary heart disease. Methods Patients (60 cases) with coronary heart disease in Department of Cardiovascular Medicine of Lingao People's Hospital from May 2015 to February 2016 were divided into control and treatment groups according to different treatments, and each group had 30 cases. All patients in two groups were treated with the conventional therapy. Patients in the control group were po administered with Trimetazidine Dihydrochloride Tablets, 20 mg/time, three times daily. Patients in the treatment group were po administered with Huoxue Tongmai Tablets on the basis of the control group, 5 tablets/time, three times daily. The patients in two groups were treated for 4 weeks. After treatment, the clinical efficacies were evaluated, and the improvement of serum inflammatory factors levels, vascular endothelial functions, and cardiac function indexes before and after treatment in two groups was compared. Results After treatment, the clinical efficacies in the control and treatment groups were 80.00% and 96.67%, respectively, and there were differences between two groups (P<0.05). After treatment, hs-CRP, and TNF-α, and MDA levels in two groups were significantly decreased, and the differences were statistically significant in the same group (P<0.05). And these serum inflammatory factors levels in the treatment group were decreased more significantly than those in the control group, with significant difference between two groups (P<0.05). After treatment, ET-1 levels were significantly decreased, but NO and CGRP levels were increased, and the differences were statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment, LVEDD and LVPWd in two groups were decreased, and LVEF index was increased, and there were differences in the same group (P<0.05). And these cardiac function indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). Conclusion Huoxue Tongmai Tablets combined with trimetazidine has a good clinical curative effect in treatment of coronary heart disease, can significantly improve cardiac and endothelial functions with inflammatory factor levels reducing, which has a certain clinical application value.